{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:09:12Z","timestamp":1790712552657,"version":"4.1.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2015R1A2A2A01004118"],"award-info":[{"award-number":["2015R1A2A2A01004118"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2015R1A2A2A04004806"],"award-info":[{"award-number":["2015R1A2A2A04004806"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medical Research Center Program","award":["2015R1A5A2009124"],"award-info":[{"award-number":["2015R1A5A2009124"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.jconrel.2018.05.018","type":"journal-article","created":{"date-parts":[[2018,5,16]],"date-time":"2018-05-16T23:43:44Z","timestamp":1526514224000},"page":"84-96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":196,"special_numbering":"C","title":["Regulatory T cell-targeted hybrid nanoparticles combined with immuno-checkpoint blockage for cancer immunotherapy"],"prefix":"10.1016","volume":"281","author":[{"given":"Wenquan","family":"Ou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj Kumar","family":"Thapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zar Chi","family":"Soe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Gautam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Hoon","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee-Heon","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sae Kwang","family":"Ku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Gon","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chul Soon","family":"Yong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4929-851X","authenticated-orcid":false,"given":"Jong Oh","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2018.05.018_bb0005","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.immuni.2009.05.002","article-title":"Natural and adaptive Foxp3+ regulatory T cells: more of the same or a division of labor?","volume":"30","author":"Curotto de Lafaille","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2018.05.018_bb0010","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cell.2008.05.009","article-title":"Regulatory T cells and immune tolerance","volume":"133","author":"Sakaguchi","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2018.05.018_bb0015","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nri2343","article-title":"How regulatory T cells work","volume":"8","author":"Vignali","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2018.05.018_bb0020","doi-asserted-by":"crossref","first-page":"26R","DOI":"10.1203\/PDR.0b013e31819e76c7","article-title":"The Treg\/Th17 cell balance: a new paradigm for autoimmunity","volume":"65","author":"Eisenstein","year":"2009","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.jconrel.2018.05.018_bb0025","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1007\/s00262-008-0507-4","article-title":"Selective accumulation of differentiated FOXP3+CD4+ T cells in metastatic tumor lesions from melanoma patients compared to peripheral blood","volume":"57","author":"Jandus","year":"2008","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.jconrel.2018.05.018_bb0030","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s12253-010-9254-x","article-title":"FOXP3+ cell density in primary tumor has no prognostic impact in patients with cutaneous malignant melanoma","volume":"16","author":"Lad\u00e1nyi","year":"2010","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.jconrel.2018.05.018_bb0035","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.1182\/blood-2008-06-163048","article-title":"FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions","volume":"112","author":"Ahmadzadeh","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2018.05.018_bb0040","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1365-2133.2007.08057.x","article-title":"Evaluation of tumour-infiltrating CD4+CD25+FOXP3+ regulatory T cells in human cutaneous benign and atypical naevi, melanomas and melanoma metastases","volume":"157","author":"Mourmouras","year":"2007","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jconrel.2018.05.018_bb0045","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1600-0625.2011.01260.x","article-title":"Prognostic value of tumor-infiltrating Foxp3+ T-cell subpopulations in metastatic melanoma","volume":"20","author":"Knol","year":"2011","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.jconrel.2018.05.018_bb0050","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1002\/eji.201041093","article-title":"Efficient Treg depletion induces T-cell infiltration and rejection of large tumors","volume":"40","author":"Li","year":"2010","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jconrel.2018.05.018_bb0055","doi-asserted-by":"crossref","first-page":"19446","DOI":"10.1073\/pnas.0706832104","article-title":"CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes\/macrophages","volume":"104","author":"Tiemessen","year":"2007","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2018.05.018_bb0060","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ccr.2008.04.001","article-title":"TNFR1 signaling and IFN-\u03b3 signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis","volume":"13","author":"M\u00fcller-Hermelink","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jconrel.2018.05.018_bb0065","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.4049\/jimmunol.181.10.6955","article-title":"Imatinib mesylate inhibits CD4+CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL(negative) tumors","volume":"181","author":"Larmonier","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2018.05.018_bb0070","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1182\/blood.V126.23.2219.2219","article-title":"Tyrosine kinase inhibitor imatinib enhances tumor immunity by depleting functionally mature regulatory T cells","volume":"126","author":"Noguchi","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2018.05.018_bb0075","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1021\/bc400070q","article-title":"In Vivo targeting of Intratumor regulatory T cells using PEG-modified single-walled carbon nanotubes","volume":"24","author":"Sacchetti","year":"2013","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2018.05.018_bb0080","series-title":"Neuropilins in Physiological and Pathological Angiogenesis","author":"Staton","year":"2007"},{"key":"10.1016\/j.jconrel.2018.05.018_bb0085","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2015.00125","article-title":"Neuropilin-1 as therapeutic target for malignant melanoma","volume":"5","author":"Graziani","year":"2015","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2018.05.018_bb0090","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nri1003","article-title":"Semaphorins in interactions between T cells and antigen-presenting cells","volume":"3","author":"Kikutani","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2018.05.018_bb0095","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/eji.200324799","article-title":"Frontline: Neuropilin-1: a surface marker of regulatory T cells","volume":"34","author":"Bruder","year":"2004","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jconrel.2018.05.018_bb0100","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1084\/jem.20111497","article-title":"Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growth","volume":"209","author":"Hansen","year":"2012","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jconrel.2018.05.018_bb0105","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nature12428","article-title":"Stability and function of regulatory T cells is maintained by a neuropilin-1\u2013semaphorin-4a axis","volume":"501","author":"Delgoffe","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2018.05.018_bb0110","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1111\/febs.13656","article-title":"Targeting regulatory T cells in tumors","volume":"283","author":"Liu","year":"2016","journal-title":"FEBS J."},{"key":"10.1016\/j.jconrel.2018.05.018_bb0115","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ccr.2009.10.013","article-title":"Tissue-penetrating delivery of compounds and nanoparticles into tumors","volume":"16","author":"Sugahara","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jconrel.2018.05.018_bb0120","doi-asserted-by":"crossref","first-page":"16157","DOI":"10.1073\/pnas.0908201106","article-title":"C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration","volume":"106","author":"Teesalu","year":"2009","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2018.05.018_bb0125","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1038\/onc.2011.537","article-title":"Transtumoral targeting enabled by a novel neuropilin-binding peptide","volume":"31","author":"Roth","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.jconrel.2018.05.018_bb0130","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.biomaterials.2015.08.035","article-title":"Tumor-specific penetrating peptides-functionalized hyaluronic acid\u2011d-\u03b1-tocopheryl succinate based nanoparticles for multi-task delivery to invasive cancers","volume":"71","author":"Liang","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2018.05.018_bb0135","doi-asserted-by":"crossref","first-page":"33412","DOI":"10.1021\/acsami.6b08153","article-title":"Gemcitabine and antisense-microRNA co-encapsulated PLGA\u2013PEG polymer nanoparticles for hepatocellular carcinoma therapy","volume":"8","author":"Devulapally","year":"2016","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2018.05.018_bb0140","series-title":"Biodegradable Poly(D,L-Lactic-Co-Glycolic Acid)-Based Micro\/Nanoparticles for Sustained Release of Protein Drugs: a Review","author":"Ansary","year":"2014"},{"key":"10.1016\/j.jconrel.2018.05.018_bb0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0168942","article-title":"BJ-3105, a 6-Alkoxypyridin-3-ol analog, impairs T cell differentiation and prevents experimental autoimmune encephalomyelitis disease progression","volume":"12","author":"Timilshina","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2018.05.018_bb0150","doi-asserted-by":"crossref","first-page":"9280","DOI":"10.1021\/acsami.6b09163","article-title":"Development of bioactive PEGylated nanostructured platforms for sequential delivery of doxorubicin and Imatinib to overcome drug resistance in metastatic tumors","volume":"9","author":"Gupta","year":"2017","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2018.05.018_bb0155","doi-asserted-by":"crossref","first-page":"8154","DOI":"10.1002\/adma.201402996","article-title":"Immunological responses triggered by Photothermal therapy with carbon nanotubes in combination with anti-CTLA-4 therapy to inhibit Cancer metastasis","volume":"26","author":"Wang","year":"2014","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2018.05.018_bb0160","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7150\/thno.7193","article-title":"Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target?","volume":"4","author":"Kobayashi","year":"2014","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2018.05.018_bb0165","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.addr.2010.04.009","article-title":"The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect","volume":"63","author":"Fang","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2018.05.018_bb0170","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1021\/nn800275r","article-title":"Self-assembled lipid\u2212polymer hybrid nanoparticles: a robust drug delivery platform","volume":"2","author":"Zhang","year":"2008","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2018.05.018_bb0175","doi-asserted-by":"crossref","first-page":"5116","DOI":"10.1016\/j.actbio.2014.08.021","article-title":"Layer-by-layer assembly of liposomal nanoparticles with PEGylated polyelectrolytes enhances systemic delivery of multiple anticancer drugs","volume":"10","author":"Ramasamy","year":"2014","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jconrel.2018.05.018_bb0180","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/sj.bjc.6605539","article-title":"Neuropilin-1 antagonism in human carcinoma cells inhibits migration and enhances chemosensitivity","volume":"102","author":"Jia","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2018.05.018_bb0185","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.biomaterials.2012.08.072","article-title":"pH-sensitive poly(histidine)-PEG\/DSPE-PEG co-polymer micelles for cytosolic drug delivery","volume":"34","author":"Wu","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2018.05.018_bb0190","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2014.00108","article-title":"Biomolecular corona on nanoparticles: a survey of recent literature and its implications in targeted drug delivery","volume":"2","author":"Pearson","year":"2014","journal-title":"Front. Chem."},{"key":"10.1016\/j.jconrel.2018.05.018_bb0195","series-title":"Endocytosis of Particle Formulations by Macrophages and its Application to Clinical Treatment","author":"Hirota","year":"2012"},{"key":"10.1016\/j.jconrel.2018.05.018_bb0200","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.ejps.2010.09.006","article-title":"Particle size affects the cellular response in macrophages","volume":"41","author":"Yue","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2018.05.018_bb0205","first-page":"288","article-title":"Effect of partial PEGylation on particle uptake by macrophages","volume":"9","author":"Sanchez","year":"2017","journal-title":"Nano"},{"key":"10.1016\/j.jconrel.2018.05.018_bb0210","doi-asserted-by":"crossref","first-page":"7593","DOI":"10.4049\/jimmunol.179.11.7593","article-title":"Role of STAT3 in CD4+CD25+FOXP3+ regulatory lymphocyte generation: implications in graft-versus-host disease and antitumor immunity","volume":"179","author":"Pallandre","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2018.05.018_bb0215","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1182\/blood-2006-02-004747","article-title":"IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo","volume":"108","author":"Zorn","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2018.05.018_bb0220","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1126\/science.1172702","article-title":"CD4+ regulatory T cells control Th17 responses in a Stat3-dependent manner","volume":"326","author":"Chaudhry","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2018.05.018_bb0225","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/2191-219X-2-39","article-title":"Emerging role of radiolabeled nanoparticles as an effective diagnostic technique","volume":"2","author":"de Barros","year":"2012","journal-title":"EJNMMI Res."},{"key":"10.1016\/j.jconrel.2018.05.018_bb0230","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1007\/s11095-012-0958-3","article-title":"Effects of particle size and surface modification on cellular uptake and biodistribution of polymeric nanoparticles for drug delivery","volume":"30","author":"Kulkarni","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2018.05.018_bb0235","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1016\/j.bmc.2009.02.043","article-title":"Nanoparticles in cellular drug delivery","volume":"17","author":"Faraji","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.jconrel.2018.05.018_bb0240","doi-asserted-by":"crossref","DOI":"10.1038\/srep25613","article-title":"Distribution of systemically administered nanoparticles reveals a size-dependent effect immediately following cardiac Ischaemia-reperfusion injury","volume":"6","author":"Lundy","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2018.05.018_bb0245","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/jbio.200910005","article-title":"Circulation and distribution of gold nanoparticles and induced alterations of tissue morphology at intravenous particle delivery","volume":"2","author":"Terentyuk","year":"2009","journal-title":"J. Biophotonics"},{"key":"10.1016\/j.jconrel.2018.05.018_bb0250","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/nm.2438","article-title":"Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido","volume":"17","author":"Balachandran","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2018.05.018_bb0255","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1158\/1078-0432.CCR-03-0155","article-title":"Plasma and cerebrospinal fluid pharmacokinetics of Imatinib after administration to nonhuman Primates","volume":"10","author":"Neville","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2018.05.018_bb0260","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.nano.2016.12.010","article-title":"Synergistic anticancer activity of combined histone deacetylase and proteasomal inhibitor-loaded zein nanoparticles in metastatic prostate cancers","volume":"13","author":"Thapa","year":"2017","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2018.05.018_bb0265","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/nm.2438","article-title":"Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido","volume":"17","author":"Balachandran","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2018.05.018_bb0270","doi-asserted-by":"crossref","unstructured":"A.E. Overacre-Delgoffe, M. Chikina, R.E. Dadey, H. Yano, E.A. Brunazzi, G. Shayan, W. Horne, J.M. Moskovitz, J.K. Kolls, C. Sander, Y. Shuai, D.P. Normolle, J.M. Kirkwood, R.L. Ferris, G.M. Delgoffe, T.C. Bruno, C.J. Workman, D.A.A. Vignali, Interferon-\u03b3 drives Treg fragility to promote anti-tumor immunity, Cell 169, 1130-1141.","DOI":"10.1016\/j.cell.2017.05.005"},{"key":"10.1016\/j.jconrel.2018.05.018_bb0275","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aan5692","article-title":"A melanin-mediated cancer immunotherapy patch","volume":"2","author":"Ye","year":"2017","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.jconrel.2018.05.018_bb0280","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2147\/CMAR.S57550","article-title":"New modalities of cancer treatment for NSCLC: focus on immunotherapy","volume":"6","author":"Davies","year":"2014","journal-title":"Cancer Manag. Res."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365918302839?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365918302839?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T00:16:36Z","timestamp":1571357796000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365918302839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":56,"alternative-id":["S0168365918302839"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2018.05.018","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Regulatory T cell-targeted hybrid nanoparticles combined with immuno-checkpoint blockage for cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2018.05.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}